0QAH.L - Merck & Co., Inc.
| Previous close | 89.51 |
| Open | 92.36 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 89.12 - 89.48 |
| 52-week range | 89.12 - 89.48 |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | 0.36 |
| PE ratio (TTM) | 0.16 |
| EPS (TTM) | 5.59 |
| Earnings date | 01 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireFDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
RAHWAY, N.J., June 01, 2023--FDA Approves LYNPARZA Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated mCRPC
Business WireKEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
RAHWAY, N.J. & NUTLEY, N.J., May 25, 2023--KEYTRUDA® Plus LENVIMA® Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced RCC
Business WireMerck Announces Third-Quarter 2023 Dividend
RAHWAY, N.J., May 23, 2023--Merck Announces Third-Quarter 2023 Dividend
Yahoo Finance VideoFed, labor market concerns showing 'some dents in the armor of the consumer': Strategist
Hennion & Walsh CIO Kevin Mahn joins Yahoo Finance Live to discuss the state of the consumer amid retail earnings, Target Q1 earnings, Walmart earnings preview, Fed rate hikes, inflation, and the impact on consumer spending.
Business WireMerck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting
RAHWAY, N.J., May 15, 2023--Merck ASCO Curtain Raiser
Yahoo Finance UKUS stocks and FTSE 100 lower as BoE hikes rates again
Investors are gearing up for an announcement on UK interest rates which is due at noon.
Business WireMerck to Participate in Bank of America Securities 2023 Healthcare Conference
RAHWAY, N.J., May 03, 2023--Merck to Participate in Bank of America Securities 2023 Healthcare Conference
Business WireUpdate on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer
RAHWAY, N.J., April 28, 2023--Update on FDA Advisory Committee Vote on LYNPARZA Plus Abiraterone and Prednisone or Prednisolone in First-Line mCRPC
Yahoo Finance VideoDrugmakers brace for serious headwinds ahead
Yahoo Finance’s Anjalee Khemlanin joins the Live show to discuss quarterly earnings for Abbvie, Merck & Company, and Biogen, the headwinds facing drugmakers, and what they mean for investors watching the pharmaceuticals space.
Business WireMerck Announces First-Quarter 2023 Financial Results
RAHWAY, N.J., April 27, 2023--Merck Announces First-Quarter 2023 Financial Results
Yahoo Finance VideoPrometheus Biosciences stock soars amid $10.8 billion acquisition deal by Merck
Yahoo Finance Live highlights Prometheus Bioscience's stock performance amid the company's deal with pharmaceutical giant Merck.
Yahoo FinanceModerna stock plunges following mixed analyst reviews of cancer vaccine data
Moderna stock plunges following mixed analyst reviews of cancer vaccine data
Yahoo Finance VideoMerck agrees to acquire Prometheus Biosciences
Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss news that Merck has agreed to acquire biotechnology company Prometheus Biosciences.
Business WireMerck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer
RAHWAY, N.J., April 16, 2023--Merck’s KEYTRUDA® Plus Chemotherapy Significantly Improved OS Compared to Chemotherapy Alone in Patients With Advanced or Unresectable BTC
Business WireMerck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
RAHWAY, N.J. & SAN DIEGO, April 16, 2023--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. ("Prometheus") (Nasdaq: RXDX) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.
Business WireFDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
RAHWAY, N.J., April 13, 2023--KEYTRUDA KEYNOTE-859 Filing Acceptance
Business WireMerck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017)
RAHWAY, N.J. & NUTLEY, N.J., April 07, 2023--Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA plus LENVIMA In Certain Patients With Advanced Melanoma and Metastatic Colorectal Cancer
ACCESSWIREMRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant
Business WireFDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
RAHWAY, N.J., April 03, 2023--FDA Approves KEYTRUDA in Combination With Padcev for First-Line Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Cancer
Business WireMerck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27
RAHWAY, N.J., March 30, 2023--Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27
Business WireFDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
RAHWAY, N.J., March 29, 2023--FDA Converts to Full Approval Indication for KEYTRUDA for Certain Adult and Pediatric Patients With Advanced MSI-H or dMMR Solid Tumors
Yahoo Finance VideoStocks trade higher at the open, tech sees gains
Yahoo Finance Live’s Brad Smith breaks down how stocks are trading following the opening bell on Wednesday.
Business WireKEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status
RAHWAY, N.J., March 27, 2023--KEYTRUDA® Plus Chemotherapy Significantly Improved PFS Compared to Chemo Alone as 1L Therapy for Advanced or Recurrent Endometrial Carcinoma
Business WireMerck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
RAHWAY, N.J., March 16, 2023--Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A in Previously Treated Patients with mNSCLC
Business WireKEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma
RAHWAY, N.J. & KINGSTON, Ontario, March 10, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) today announced that the Phase 2/3 CCTG IND.227/KEYNOTE-483 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met its primary endpoint of overall survival (OS) for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. IND.227 was sponsored